Elevance Health reaffirms 2026 EPS guidance of at least $22.00 and adjusted EPS of at least $29.00

Elevance Health, Inc.

2026-Q3 EPS reported $21.01 vs consensus $4.73 ▲ beat (+344.3%)

Elevance Health reaffirmed full-year 2026 shareholders' earnings guidance of at least $22.00 per diluted share.
Guidance includes approximately $7.00 per diluted share of net unfavorable items; adjusted earnings guidance is at least $29.00.
The company reaffirmed 2026 benefit expense ratio guidance of 90.2%, plus or minus 50 basis points.
Officers expect to speak with investors and analysts this week and cited no other adjustment items beyond Q3 2026 earnings.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.